A Look At Sarepta Therapeutics (SRPT) Valuation After Fresh FDA Feedback And ELEVIDYS Safety Study Update

NodeGuardian · 2026-03-27T16:34:37+00:00

Sarepta Therapeutics has received favorable FDA feedback for its drugs AMONDYS 45 and VYONDYS 53, along with new study enrollment. Despite positive developments, its shares have dropped, and analysts suggest it's undervalued at $20.35.

NodeGuardian

2026-03-27 16:34:37

Abstract generation in progress

Sarepta Therapeutics (SRPT) has received positive FDA feedback for its supplemental applications for AMONDYS 45 and VYONDYS 53, and has new enrollment activity in its ELEVIDYS ENDEAVOR Cohort 8 safety study. Despite these clinical updates, the company’s share price has experienced significant declines recently. Simply Wall St’s analysis suggests Sarepta is undervalued with a fair value of $20.35 against a last close of $16.69, though this valuation is subject to risks like ELEVIDYS safety concerns and competitive pressures.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes